½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 7 March 2022 ¨C 20:00 (CET) ¨C Regulated information 

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, ½ðºÌÓéÀÖ³Ç announces that, following exercises of stock options by members of its personnel, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

In addition to these exercises, on 2 March 2022, in accordance with the vesting rules under its 2020 and 2021 LTI plans, ½ðºÌÓéÀÖ³Ç SA/NV has delivered for free a total of 328 ½ðºÌÓéÀÖ³Ç shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 2 March 2022 was € 99,82.

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news